Martínez G H, Castañeda A, Correa J E
Research Department, Family Planning Clinic, PROFAMILIA, Medellín, Colombia.
Contraception. 1998 Jul;58(1):21-7. doi: 10.1016/s0010-7824(98)00058-4.
Perlutal (other names: Topasel, Perlutan) is a once-a-month injectable contraceptive that contains 10 mg estradiol enanthate and 150 mg dihydroxyprogesterone acetophenide. A prospective trial was conducted in 216 women in Medellín, Colombia, over five years (5,462 woman-months) to establish the rates of the different vaginal bleeding patterns during the use of Perlutal, and to assess their relation with discontinuation of the Perlutal regimen. It was found that with the use of Perlutal, the duration of menstrual bleeding decreased from 3.9 to 2.7 days (p < 0.01), and that the incidence of dysmenorrhea decreased from 31% to 1.6% (p < 0.01). At one year of follow-up, the incidence of altered bleeding patterns was 5.1%. The discontinuation rate due to an altered bleeding pattern was 3.9%. It is concluded that the low incidence of altered bleeding patterns observed with the use of Perlutal leads to a low discontinuation rate among users.
佩鲁塔尔（其他名称：托帕塞尔、佩鲁坦）是一种每月注射一次的避孕药，含有10毫克庚酸雌二醇和150毫克苯乙酮二羟孕酮。在哥伦比亚麦德林对216名女性进行了一项为期五年（5462个妇女月）的前瞻性试验，以确定使用佩鲁塔尔期间不同阴道出血模式的发生率，并评估其与佩鲁塔尔方案停药的关系。研究发现，使用佩鲁塔尔后，月经出血持续时间从3.9天降至2.7天（p<0.01），痛经发生率从31%降至1.6%（p<0.01）。随访一年时，出血模式改变的发生率为5.1%。因出血模式改变导致的停药率为3.9%。结论是，使用佩鲁塔尔时观察到的出血模式改变发生率较低，导致使用者停药率较低。
